ASCO Names Dr. Clifford A. Hudis as Incoming CEO

ASCO Names Dr. Clifford A. Hudis as Incoming CEO

Julie Vose, MD, MBA, FASCO

@DrJulieVose
Mar 23, 2016 9:42 AM

It is with great pleasure that I write to inform you that Clifford A. Hudis, MD, FACP, has been named as the new Chief Executive Officer of ASCO, replacing Dr. Allen Lichter who is retiring later this year. Dr. Hudis will assume the office at ASCO Headquarters in Alexandria, VA, on June 27.

When the Board of Directors began its executive search nearly a year ago, we couldn’t have imagined finding a candidate more ideally suited for the position. Dr. Hudis is one of the most highly respected, well-regarded oncology leaders in the world.

As we welcome our incoming CEO, I also would like to take this opportunity to publicly acknowledge Dr. Lichter for his 10 tremendous years of service to ASCO. In the decade since he became ASCO’s CEO, the Society has experienced rapid growth and launched important new initiatives to improve the quality and value of cancer care. During his tenure, ASCO reached 40,000 members, including more than 13,000 international members and many allied health professionals. Among other significant initiatives, Dr. Lichter oversaw the launch of CancerLinQ™, ASCO’s big-data initiative to improve patient care, and the 2015 establishment of ASCO’s Clinical Affairs Department, which provides services, education, and resources to support oncology practices of all sizes. He leaves ASCO in an incredibly strong position to meet the needs of physicians and patients worldwide.

It’s likely that many of you already know Dr. Hudis from interactions during his more than 20 years of service to the Society. In addition to his time as President from 2013 to 2014, he has held a number of prominent roles since joining ASCO in 1991. He served on ASCO’s Board of Directors from 2009 to 2015, and was Board Treasurer from 2009 to 2012 and a member of the Executive and Planning Committees from 2009 to 2013. He was Co-Chair of the Board’s Finance and Governance Subcommittee and Chair of the Finance Committee from 2009 to 2012. Dr. Hudis served as Chair of ASCO’s Integrated Technology Committee and Co-Chair of the Breast Cancer Symposium Program Committee. He also served multiple terms on the ASCO Annual Meeting Scientific Program Committee, and helped lead ASCO panels charged with assessing evidence on breast cancer therapy. He has served on CancerLinQ’s Board of Governors since 2014, and as CEO of ASCO he will automatically become Chair of that body.

Dr. Hudis is one of the nation’s leading specialists in breast cancer treatment and a recognized expert in cancer prevention. He obtained his medical degree from the Medical College of Pennsylvania, where he completed his internship and residency, and completed his fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center (MSKCC). He is currently a Professor of Medicine at Weill Cornell Medical College and Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at MSKCC, where he has also served in a number of administrative roles that support the institution’s faculty and mission, developed a robust integration of the program’s geographically distributed clinical care sites, and mentored a large number of faculty and trainees who are now independent clinical and scientific leaders.

In addition, Dr. Hudis has received many awards and honors, including the 2008 Drexel University College of Medicine WMC/MCP Achievement Award, which recognizes graduates of the Medical College of Pennsylvania who are highly acclaimed for their service and leadership in the medical profession. In 2016 he became a Fellow of the American Society of Clinical Oncology (FASCO) based on his years of service.

No one could be better equipped to advance ASCO’s vision in a time of rapid technologic, scientific, and societal change. As a recent President and one of ASCO’s most active volunteers for over two decades, Dr. Hudis has shown a remarkable commitment to our mission of improving patient care. He has helped usher in some of ASCO’s boldest initiatives, and I’m very pleased that ASCO will benefit from his vision and enthusiasm for years to come.

Please join me in warmly welcoming Dr. Hudis as the new CEO of ASCO. We look forward to a smooth transition in the coming months, and to having his full-time leadership at ASCO.

Back to Top